

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1 to 4 (canceled).

Claim 5 (currently amended). A method for inhibiting a viral microbial infection in a cell, comprising contacting the cell with an imidazoquinoline compound or poly I:C to a molecule that stimulate[[s]] induction of IRF3 in the cell, thereby inhibiting the viral microbial infection.

Claims 6 to 9 (canceled).

Claim 10 (currently amended). The method of claim 7, wherein the cell is contacted with the molecule that stimulates the TLR is a TLR ligand selected from a group consisting of a bacterial antigen, LPS, lipid A, taxol, a viral antigen, RSV F protein, double stranded RNA, imidazoquinoline compounds, and poly I:C.

Claims 11 to 19 (canceled).

Claim 20 (currently amended). A method for inhibiting viral replication in a cell by stimulating the TLR3/TLR4 and IRF3 pathways in the cell comprising contacting the cell with an imidazoquinoline compound or poly I:C molecule that stimulates the TLR3/TLR4 and IRF3 pathways, thereby inhibiting the viral replication in the cell.

Claim 21 (currently amended). The method of claim 20, wherein the cell is contacted with the molecule that stimulates the TLR3/TLR4 and IRF3 pathways is a TLR ligand selected from a group consisting of bacterial antigen, LPS, lipid A, taxol, viral antigen, RSV F protein, double stranded RNA, imidazoquinoline compounds, and poly I:C.

Claims 22 to 24 (canceled).

Claim 25 (new). The method of claim 5, wherein the cell is a macrophage.

Claim 26 (new). The method of claim 20, wherein the cell is a macrophage.